MEDANTA2022-10-012022-12-31 MEDANTA2022-10-012022-12-31 MEDANTA2022-10-012022-12-31in-bse-fin:OneOperatingExpenses01Member MEDANTA2022-10-012022-12-31in-bse-fin:OneOperatingExpenses02Member MEDANTA2022-10-012022-12-31in-bse-fin:OneOperatingExpenses03Member MEDANTA2022-10-012022-12-31in-bse-fin:FourOperatingExpenses01Member MEDANTA2022-10-012022-12-31in-bse-fin:FourOperatingExpenses02Member MEDANTA2022-10-012022-12-31in-bse-fin:FourOperatingExpenses03Member MEDANTA2022-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543654 MEDANTA NA Global Health Limited Equity 2022-04-01 2023-03-31 2023-02-13 2023-02-04 INR Lakhs Third quarter 15:30:00 18:20:00 2023-02-13 2023-02-13 Not applicable Single segment Healthcare services 2022-10-01 2022-12-31 Unaudited Standalone 4897860000.00 125229000.00 5023089000.00 1063467000.00 81521000.00 9540000.00 1336063000.00 64922000.00 216156000.00 1452483000.00 4224152000.00 798937000.00 0.00 798937000.00 255598000.00 -44387000.00 211211000.00 0.00 587726000.00 0.00 0.00 0.00 0.00 587726000.00 1575000.00 589301000.00 589301000.00 0.00 268185000.00 2 2.25 2.25 0.00 0.00 2.25 2.25 1 The above standalone financial results for the quarter and nine months period ended 31 December 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 February 2023 and a limited review of the same has been carried out by the statutory auditors. 2 These standalone financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (‘the Act’), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 3 The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment. The Company is operating in India which constitutes a single geographical segment. 4 During the nine months period ended 31 December 2022, the company has incorporated a wholly owned subsidiary namely, GHL Pharma and Diagnostic Private Limited. Additionally, the Company has infused equity amounting to Rs. 2,000 lakhs and Rs. 1,001 lakhs in its wholly owned subsidiaries, namely, Global Health Patliputra Private Limited and GHL Pharma and Diagnostic Private Limited, respectively. 5 For Point no. 5, please refer the result PDF file uploaded. 6 During the nine months period ended 31 December 2022, the Company has allotted 80,000 equity shares under the Company’s Employee Stock Options Schemes on exercise of vested options by eligible employees. 7 Previous period figures have been regrouped/reclassified to conform to the current period's classification. Single segment 2022-04-01 2022-12-31 Unaudited Standalone 14565363000.00 335808000.00 14901171000.00 3176299000.00 253082000.00 14951000.00 4003565000.00 197824000.00 657344000.00 4122994000.00 12426059000.00 2475112000.00 0.00 2475112000.00 750723000.00 -98509000.00 652214000.00 0.00 1822898000.00 0.00 0.00 0.00 0.00 1822898000.00 4318000.00 1827216000.00 1827216000.00 0.00 268185000.00 2 7.12 7.11 0.00 0.00 7.12 7.11 Impairment losses on financial assets 27512000.00 Other expenses 974667000.00 Retainers and consultants fee 450304000.00 Impairment losses on financial assets 46777000.00 Other expenses 2733789000.00 Retainers and consultants fee 1342428000.00 2104000.00 5770000.00 529000.00 1452000.00